#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Hungatella Effluvii, Live

A new drug called VE202 is being tested in clinical trials for patients with mild to moderate ulcerative colitis. This article explores the ongoing research on VE202, a capsule containing various live bacterial strains, and its potential to improve the symptoms of ulcerative colitis. We’ll discuss the trial’s objectives, eligibility criteria, and what this could mean for patients suffering from this inflammatory bowel disease.

Table of Contents

What is VE202?

VE202 is an investigational drug being studied as a potential treatment for mild to moderate ulcerative colitis. It is a capsule containing live bacteria, specifically various strains of Clostridia and Bacilli.[1] These bacteria are part of a group known as live biotherapeutic products, which are living organisms used to prevent, treat, or cure a disease.

Target Condition: Mild to Moderate Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding. The condition is classified as mild to moderate when symptoms are present but not severe enough to require hospitalization.[1]

How VE202 Works

While the exact mechanism of action is not fully understood, VE202 is designed to work by introducing beneficial bacteria into the gut. These bacteria may help to:

  • Restore balance to the gut microbiome (the community of microorganisms living in the intestines)
  • Reduce inflammation in the colon
  • Improve the function of the intestinal barrier
By doing so, VE202 aims to alleviate the symptoms of ulcerative colitis and potentially improve the overall health of the colon.[1]

Current Research on VE202

VE202 is currently being studied in a Phase 2 clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental and is not yet approved for general use. The main goals of the current study are:

  1. To evaluate how effective VE202 is in improving the appearance of the colon lining (as seen through a flexible sigmoidoscopy) after 8 weeks of treatment
  2. To assess the safety of VE202
The study is randomized, double-blind, and placebo-controlled, which means that participants are randomly assigned to receive either VE202 or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.[1]

Eligibility Criteria for the Study

To participate in the VE202 study, patients must meet certain criteria. Some key requirements include:

  • Being 18 to 75 years old
  • Having a diagnosis of ulcerative colitis for at least 3 months
  • Having active mild to moderate UC, as determined by specific scoring systems
  • Not having received certain other types of treatments for UC in the past
There are also several conditions that would prevent someone from participating, such as having Crohn’s disease, active infections, or certain other medical conditions.[1]

Potential Benefits of VE202

If proven effective, VE202 could offer several potential benefits for patients with mild to moderate ulcerative colitis:

  • A new treatment option for those who haven’t responded well to other therapies
  • A potentially more natural approach to treating UC by using beneficial bacteria
  • Possible improvement in symptoms and quality of life
  • Potential for fewer side effects compared to some existing treatments
However, it’s important to note that these potential benefits are still being studied and are not guaranteed.[1]

Safety Considerations

As with any investigational treatment, the safety of VE202 is a primary concern in the current study. The researchers are carefully monitoring for any side effects or adverse reactions. Some safety measures in place include:

  • Regular check-ups and monitoring throughout the study
  • Strict criteria for who can participate in the study
  • Careful tracking of any side effects or adverse events
Patients considering participating in this or any clinical trial should discuss the potential risks and benefits with their healthcare provider.[1]

Aspect Details
Drug Name VE202
Condition Treated Mild to moderate ulcerative colitis
Trial Phase Phase 2
Main Objective Evaluate efficacy in terms of endoscopic response after 8 weeks of treatment
Treatment Duration 8 weeks
Key Eligibility Criteria Adults 18-75 years old, diagnosed with UC for at least 3 months, active mild to moderate disease
Primary Endpoints Endoscopic response rate, treatment-related adverse events
Drug Composition Multiple strains of live bacteria (Clostridia and Bacilli species)
Administration Route Oral capsule

FAQ

  • What is VE202 and how does it work? VE202 is a capsule containing multiple strains of live bacteria, including various Clostridia and Bacilli species. It's designed to help restore balance to the gut microbiome, which may help reduce inflammation and improve symptoms in people with ulcerative colitis.
  • Who is eligible to participate in the VE202 clinical trial? The trial is open to adults aged 18-75 with a diagnosis of mild to moderate ulcerative colitis for at least 3 months. Participants must have active disease and meet specific criteria regarding disease severity and previous treatments. Some exclusions apply, such as a history of Crohn's disease or recent use of certain medications.
  • What is the main goal of the VE202 clinical trial? The primary objective is to evaluate the efficacy of VE202 in improving endoscopic response after 8 weeks of treatment. This means checking if there's a reduction in inflammation of the colon lining as seen during a flexible sigmoidoscopy examination.
  • How long does the VE202 treatment last in the trial? The treatment period in the trial lasts for 8 weeks. During this time, participants will receive either VE202 or a placebo, and their response to the treatment will be monitored.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include improvement in ulcerative colitis symptoms and contributing to medical research. Risks may include side effects from the medication, which are being closely monitored in the trial. The study is specifically looking at serious adverse events and any grade 3 or higher treatment-related side effects to ensure patient safety.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Hungatella Effluvii, Live

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Ulcerative Colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum.
  • Endoscopic Response: An improvement in the appearance of the colon lining as seen during an endoscopic examination, such as a flexible sigmoidoscopy.
  • Flexible Sigmoidoscopy: A medical procedure that allows doctors to view the lower part of the colon using a flexible tube with a camera.
  • Placebo: An inactive substance that looks like the real medicine but has no therapeutic effect, used as a control in clinical trials.
  • Microbiome: The collection of all microorganisms, such as bacteria, that naturally live in and on our bodies, particularly in the gut.
  • Colony Forming Unit (CFU): A unit used to estimate the number of viable bacteria or fungal cells in a sample.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Modified Mayo Score: A scoring system used to assess the severity of ulcerative colitis, taking into account factors such as stool frequency, rectal bleeding, and endoscopic findings.

References

  1. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/